Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lobe Sciences Ltd C.LOBE

Alternate Symbol(s):  LOBEF

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaborations with partners, is engaged in research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolios. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd., and Altemia & Company, LLC.


CSE:LOBE - Post by User

<< Previous
Bullboard Posts
Post by BullBuyon Jun 04, 2024 5:47pm
203 Views
Post# 36072094

Dormant stock getting ready for a comeback?

Dormant stock getting ready for a comeback?

 "As we review the psychedelic market, it is clear that L-130 is a differentiated compound with a very unique profile not seen in any other product. We will pursue every avenue to ensure our share value is reflective of the potential of our science."

 

Liking the bullish stance the CEO is taking.

<< Previous
Bullboard Posts